ClinicalTrials.gg
Active, not recruitingNCT05575011Updated Oct 23, 2026

A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec

A Phase 1 interventional study of BIIB115 and BIIB115-Matching Placebo in Healthy Volunteer and Muscular Atrophy, Spinal, sponsored by Biogen. Active, not recruiting at 16 sites in 9 countries. Open to participants aged 6 Months to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Biogen · Phase 1, Interventional, and Treatment

Updated Oct 23, 20261 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
6 Months to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Muscular Atrophy, Spinal by Biogen — 5 open to participants now, 10 under way, 4 of them phase 3. Muscular Atrophy, Spinal · Biogen.

Enrollment
10th of 21
62 · median 47
Started
2022
with 3 others
Phase 1
5 of 27
1 open now
Registered
21st of 27
by date

Among the 27 studies in Muscular Atrophy, Spinal by Biogen, this one is the 10th largest by enrollment of the 21 interventional ones that give a count, is one of 4 that started in 2022, is one of 5 in phase 1, and was the 21st registered.

Muscular Atrophy, Spinal

282 studies on the registry are indexed under Muscular Atrophy, Spinal; 72 are open to participants now.

Browse Muscular Atrophy, Spinal studies →

Open to participants now

5 of the 27 studies in Muscular Atrophy, Spinal by Biogen are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 57 Muscular Atrophy, Spinal studies recruiting now, 28 (49%) set no upper age limit and 26 (46%) stop at 75 or younger; 45 take children under 18; 11 take healthy volunteers.

This study: 6 Months to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Muscular Atrophy, Spinal by Biogen, or all of them as a file.
02

Study summary

In this study, researchers will learn about a study drug called BIIB115 in healthy adult male volunteers and in participants with spinal muscular atrophy (SMA). This study will focus on children with SMA.

The main objective of the study is to learn about the safety of BIIB115 and how participants respond to different doses of BIIB115. The main question researchers want to answer is:

  • How many participants have adverse events and serious adverse events during the study?

Adverse events are unwanted health problems that may or may not be caused by the study drug.

Researchers will also learn about how the body processes BIIB115. They will do this by measuring the levels of BIIB115 in both the blood and the cerebrospinal fluid, also known as the CSF. This is the fluid around the brain and spinal cord.

The study will be split into 2 parts - Part A and Part B.

During Part A:

  • After screening, healthy volunteers will be randomly placed into 1 of 4 groups to receive either BIIB115 or a placebo. A placebo looks like the study drug but contains no real medicine.
  • Participants will receive a single dose of either BIIB115 or the placebo as an injection directly into the spinal canal on Day 1.
  • Neither the researchers nor the participants will know if the participants will receive BIIB115 or the placebo.
  • The Part A treatment and follow-up period will last for 13 months.
  • Participants will have up to 6 clinic visits and 4 phone calls.

During Part B:

  • After screening, children with SMA will be placed into 1 of 2 groups to receive BIIB115.
  • The doses of each group will be decided based on the results of Part A.
  • Both researchers and participants will know they are receiving BIIB115.
  • Participants will first receive 2 total doses of BIIB115 given at 2 different times.
  • The Part B treatment and follow-up period will last for 24 months.
  • Participants will have up to 14 clinic visits and 6 phone calls.

Part B Long-Term Extension:

  • After completing the 25 months in Part B, participants may move onto the long-term extension (LTE).
  • They will receive 5 more doses of BIIB115 at different times.
  • The Part B LTE treatment and follow-up will last for 60 months.
  • Participants will have up to 12 more clinic visits and 19 phone calls. In both Part A and Part B, participants will stay in the clinic for 24 hours after each dose so that researchers can check on their health. This 24-hour stay will not be required for the Part B LTE period.
Read the detailed description

The primary objective of the study is to assess the safety and tolerability of BIIB115 administered via intrathecal (IT) bolus injection to healthy participants in Part A, pediatric participants with spinal muscular atrophy who have previously received onasemnogene abeparvovec in Part B, and to participants who complete Part B in Part B LTE. The secondary objectives of the study is to evaluate the pharmacokinetics (PK) of BIIB115 in Parts A, B, and B LTE.

03

Conditions studied

  • Healthy Volunteer
  • Muscular Atrophy, Spinal
04

Who can participate

Ages eligible
6 Months to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

Part A:

  • Male healthy participants aged 18 to 55 years, inclusive
  • Have a of 18 to 30 kilograms per meter square (kg/m\^2), inclusive
  • Must be in good health as determined by the investigator, based on medical history and screening evaluations

Part B:

  • Age 0.5 to 12 years old, inclusive, at the time of
  • Weight ≥7 kg at the time of informed consent
  • Genetic diagnosis of SMA (5q SMA homozygous survival motor neuron 1 (SMN1) gene deletion or mutation or compound heterozygous mutation)
  • Survival motor neuron 2 (SMN2) copy number ≥1
  • Must have received intravenous (IV) onasemnogene abeparvovec per the approved label or per guidelines including the regimen and monitoring specified therein
  • Treatment with onasemnogene abeparvovec ≥180 days prior to first BIIB115 dose
  • Potential for improvement due to suboptimal clinical status secondary to SMA, as determined by the Investigator

Part B LTE

  • Completion of the assessments in Part B
  • Meets age-appropriate institutional criteria for use of anesthesia/sedation, if use is planned for study procedures (as assessed by the Investigator and either anesthesiologist or pulmonologist).

Key Exclusion Criteria:

Part A:

  • Any reason, anatomical or otherwise (including abnormal hematology/coagulation), that presents increase of risk of complication from multiple lumbar puncture (LP) procedures required for dosing and CSF collection, per the investigator discretion
  • History of any cardiac, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease, or other major disease, as determined by the Investigator
  • Chronic, recurrent, or serious infection, as determined by the investigator, within 90 days prior to screening or between screening and Day -1
  • Current enrollment or a plan to enroll in any interventional clinical study of a drug, biologic, or device, in which an treatment or approved therapy for investigational use is administered within 3 months (or 5 half-lives of the agent, whichever is longer) prior to randomization

Part B:

  • Severe or serious AEs related to onasemnogene abeparvovec therapy that are ongoing during Screening
  • Interval of \<180 days between onasemnogene abeparvovec therapy and first BIIB115 dose
  • Ongoing steroid treatment following onasemnogene abeparvovec at time of screening
  • History of drug induced liver injury or liver failure per Hy's law definition
  • History of thrombotic micrangiopathy
  • Treatment with any SMN2-splicing modifier (nusinersen or risdiplam) after receiving onasemnogene abeparvovec. Treatment with nusinersen \<12 months from the first dose of BIIB115.
  • Any reason, anatomical or otherwise (including abnormal hematology/coagulation), that presents increase of risk of complication from the LP procedures, CSF circulation, or safety assessments, including a history of hydrocephalus or implanted shunt for CSF drainage.
  • Permanent ventilation, defined as tracheostomy or ≥16 hours ventilation /day continuously for >21 days in the absence of an acute reversible event

Part B LTE:

  • Any new condition or worsening of an existing condition that, according to the Investigator, would make the participant unsuitable for inclusion, could interfere with the assessment of safety, or would compromise the ability of the participant to undergo study procedures.
  • Clinically significant abnormalities in hematology, blood chemistry parameters, or (ECGs) prior to first LTE visit that would make the participant unsuitable for inclusion as assessed by the Investigator.
  • Treatment with an approved SMN2-splicing modifier (nusinersen or risdiplam).

NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Part A: Cohort 1: BIIB115 Dose 1

    Participants will receive a single dose of BIIB115, Dose 1, via IT bolus injection, on Day 1.

    Drug: BIIB115

  • Experimental
    Part A: Cohort 2: BIIB115 Dose 2

    Participants will receive a single dose of BIIB115, Dose 2, via IT bolus injection, on Day 1.

    Drug: BIIB115

  • Experimental
    Part A: Cohort 3:BIIB115 Dose 3

    Participants will receive a single dose of BIIB115, Dose 3, via IT bolus injection, on Day 1.

    Drug: BIIB115

  • Experimental
    Part A: Cohort 4: BIIB115 Dose 4

    Participants will receive a single dose of BIIB115, Dose 4, via IT bolus injection, on Day 1.

    Drug: BIIB115

  • Placebo comparator
    Part A: Cohorts 1-4: BIIB115-Matching Placebo

    Participants will receive a single dose of BIIB115-matching placebo, via IT bolus injection, on Day 1.

    Drug: BIIB115-Matching Placebo

  • Experimental
    Part B: Cohort 5: BIIB115 Dose 3

    Pediatric SMA participants previously treated with onasemnogene abeparvovec will receive two doses of BIIB115, Dose 3, via IT bolus injection at two separate time points.

    Drug: BIIB115

  • Experimental
    Part B: Cohort 6: BIIB115 Dose 4

    Pediatric SMA participants previously treated with onasemnogene abeparvovec will receive two doses of BIIB115, Dose 4, via IT bolus injectionat two separate time points.

    Drug: BIIB115

  • Experimental
    Part B: Long Term Extension (LTE): BIIB115 Dose 4

    Pediatric SMA participants previously treated with onasemnogene abeparvovec who have completed Part B and are eligible will receive five doses of BIIB115, Dose 4, via IT bolus injection at separate time points for up to 60-month duration.

    Drug: BIIB115

Interventions

  • DrugBIIB115

    Administered as specified in the treatment arm

  • DrugBIIB115-Matching Placebo

    Administered as specified in the treatment arm

06

What researchers measure

Primary outcomes

  1. Parts A, B, and B Long Term Extension (LTE): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, in the view of the investigator, places the participant at immediate risk of death (a life-threatening event), requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect or is a medically important event.

    Time frame: Part A: Up to Day 393, Part B: Up to Day 720; Part B LTE: Up to Day 2520

Secondary outcomes

  1. Parts A, B, and B LTE: Concentration of BIIB115 in Cerebral Spinal Fluid (CSF)

    Time frame: Part A: Day 1 to Day 180, Part B: Day 1 to Day 720; Part B LTE: Day 720 to Day 2520

  2. Part A: Terminal Elimination Half-Life (t½) of BIIB115 in CSF

    Time frame: Day 1 to Day 180

  3. Parts A, B, and B LTE: Concentration of BIIB115 in Serum

    Time frame: Part A: Day 1 to Day 180, Part B: Day 1 to Day 720; Part B LTE: Day 720 to Day 2520

  4. Parts A and B: Terminal Elimination Half-Life (t½) of BIIB115 in Serum

    Time frame: Part A: Day 1 to Day 180, Part B: Day 1 to Day 720

  5. Parts A and B: Area Under the Concentration-Time Curve from Time 0 to Last Measurable Concentration (AUC0-last) of BIIB115 in Serum

    Time frame: Part A: Day 1 to Day 180, Part B: Day 1 to Day 720

  6. Parts A and B: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUCinf) of BIIB115 in Serum

    Time frame: Part A: Day 1 to Day 180, Part B: Day 1 to Day 720

  7. Parts A and B: Maximum Observed Concentration (Cmax) of BIIB115 in Serum

    Time frame: Part A: Day 1 to Day 180, Part B: Day 1 to Day 720

  8. Parts A and B: Time to Reach Maximum Observed Concentration (Tmax) of BIIB115 in Serum

    Time frame: Part A: Day 1 to Day 180, Part B: Day 1 to Day 720

07

Study locations

16 sites
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2022 (actual). Primary completion is estimated for Nov 2031, 109 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2022
First posted
Oct 12, 2022
StartActual
Oct 10, 2022
Primary completionEst.
Nov 14, 2031
CompletionEst.
Nov 14, 2031
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed
Show 1 removed
  • Kyungpook National University Hospital · Daegu, South Korea
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    1 site removed
    Show 1 removed
    • Kyungpook National University Hospital · Daegu, South Korea
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05575011
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Oct 12, 2022
Start date
Oct 10, 2022
Primary completion
Nov 14, 2031 (estimated)
Completion
Nov 14, 2031 (estimated)
Last update
Oct 23, 2026

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion